Vascular growth factors in cerebral ischemia

Molecular Neurobiology

Volumn 23, Issue 2-3, 2001, Pages 121-135

  Croll, S D ^a   Wiegand, S J ^a  

^a REGENERON PHARMACEUTICALS INC   (United States)

Author keywords

Angiopoietin; Flk; Flt; Stroke; Tie receptors; Vascular endothelial growth factor (VEGF); VEGFR1; VEGFR2

Indexed keywords

ANGIOPOIETIN; MESSENGER RNA; RECEPTOR; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN BLOOD VESSEL; BRAIN ISCHEMIA; CELL PROLIFERATION; CONTROLLED STUDY; ENDOTHELIUM CELL; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; VASCULAR ENDOTHELIUM;

EID: 0034753860     PISSN: 08937648     EISSN: None     Source Type: Journal    
DOI: 10.1385/MN:23:2-3:121     Document Type: Article

References (116)

1. 125I-albumin
2. Role of blood-brain barrier permeability in focal ischemic brain edema
3. Brain edema and cerebrovascular permeability during cerebral ischemia in rats
4. Morphological changes in acute cerebral ischemia after occlusion and reperfusion in the rat
5. Temporal profile of serum albumin extravasation following cerebral ischemia in a newly established reproducible gerbil model for vasogenic brain edema: A combined immunohistochemical and dye tracer analysis
6. Contributions of ions and albumin to the formation and resolution of ischemic brain edema
7. Role of vasogenic edema and tissue cavitation in ischemic evolution on diffusion-weighted imaging: Comparison with multiparameter MR and immunohistochemistry
8. Ischemic brain edema
9. Inflammatory gene expression in cerebral ischemia and trauma. Potential new therapeutic targets
10. Trends and future developments in the pharmacological treatment of acute ischaemic stroke
11. Inflammation and acute stroke
12. The role of inflammation after acute stroke: Utility of pursuing anti-adhesion molecule therapy
13. Reperfusion injury after focal cerebral ischemia: The role of inflammation and the therapeutic horizon
14. Advances in the vascular pathophysiology of ischemic stroke
15. Inflammatory mediators of cerebral endothelium: A role in ischemic brain inflammation
16. Anti-intercellular adhesion molecule-1 antibody reduces ischemic cell damage after transient but not permanent middle cerebral artery occlusion in the Wistar rat
17. Antibodies against adhesion molecules reduce apoptosis after transient middle cerebral artery occlusion in rat brain
18. Anti-adhesion molecule and nitric oxide protection strategies in ischemic stroke
19. P-selectin antibody reduces hemorrhage and infarct volume resulting from MCA occlusion in the rat
20. Neutrophil inhibitory factor treatment of focal cerebral ischemia in the rat
21. Angiogenesis: New insights and therapeutic potential
22. Vascular-specific growth factors and blood vessel formation
23. The role of neutrophils and platelets in a rabbit model of thromboembolic stroke
24. Characterization of microglial reaction after middle cerebral artery occlusion in rat brain
25. P-selectin and intercellular adhesion molecule-1 expression after focal brain ischemia and reperfusion
26. Expression of angiopoietin-1, angiopoietin-2, and tie receptors after middle cerebral artery occlusion in the rat
27. Hypoxia-induced vascular endothelial growth factor expression precedes neovascularization after cerebral ischemia
28. Selective accumulation of cyclooxygenase-1-expressing microglial cells/macrophages in lesions of human focal cerebral ischemia
29. Demonstration of increased endothelial-leukocyte adhesion molecule-1 mRNA expression in rat ischemic cortex
30. Apoptosis of endothelial cells in vessels affected by cerebral vasospasm
31. Identification of a new endothelial cell growth factor receptor tyrosine kinase
32. Tek, a novel tyrosine kinase gene located on mouse chromosome 4, is expressed in endothelial cells and their presumptive precursors
33. Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium
34. A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines
35. Vascular endothelial growth factors and angiogenesis
36. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor
37. Vascular endothelial growth factor: Direct neuroprotective effect in in vivo ischemia
38. Vascular endothelial growth factor is a neurotrophic factor which stimulates axonal out- growth through the flk-1 receptor
39. Developmentally regulated expression of a cell surface protein, neuropilin, in the mouse nervous system
40. Semaphorins III and IV repel hippocampal axons via two distinct receptors
41. The biology of vascular endothelial growth factor
42. Neuropilin-2 and neuropilin-1 are receptors for the 165-amino acid form of vascular endothelial growth factor (VEGF) and of placenta growth factor-2, but only neuropilin-2 functions as a receptor for the 145-amino acid form of VEGF
43. Molecular basis of angiogenesis. Roles of VEGF and VE-cadherin
44. VPF/VEGF and the angiogenic response
45. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
46. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
47. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium
48. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice
49. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice
50. Patterns of brain angiogenesis after vascular endothelial growth factor administration in vitro and in vivo
51. VEGF gene delivery to muscle: Potential role for vasculogenesis in adults
52. Physiological assessment of augmented vascularity induced by VEGF in ischemic rabbit hindlimb
53. Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model
54. Magnetic resonance mapping demonstrates benefits of VEGF-induced myocardial angiogenesis
55. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb
56. Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia
57. Arterial gene transfer of naked DNA for therapeutic angiogenesis: Early clinical results
58. Gene therapy for myocardial angiogenesis: Initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia
59. Vascular endothelial growth factor (VEGF) modulates vascular permeability and inflammation in rat brain
60. VEGF gene therapy: Stimulating angiogenesis or angioma-genesis?
61. Increased blood-brain barrier permeability and endothelial abnormalities induced by vascular endothelial growth factor
62. Effects of vascular permeability factor on the permeability of cultured endothelial cells from brain capillaries
63. Lung overexpression of the vascular endothelial growth factor gene induces pulmonary edema
64. Angiopoietin-1 protects the adult vasculature against plasma leakage
65. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome
66. Hypoxic regulation of vascular endothelial growth factor in retinal cells
67. Elevated serum levels of vascular endothelial growth factor in patients with preeclampsia
68. Increased serum vascular endothelial growth factor levels and intrathyroidal vascular area in patients with Grave's disease and Hashimoto's thyroiditis
69. Serum concentrations of vascular endothelial growth factor in collagen diseases
70. Role of vascular endothelial cell growth factor in ovarian hyperstimulation syndrome
71. Role of vascular endothelial growth factor in ovarian cancer: Inhibition of ascites formation by immunoneutralization
72. Elevated serum vascular endothelial growth factor in children and young adults with Crohn's disease
73. Serum vascular endothelial growth factor is elevated in cystic fibrosis and decreases with treatment of acute pulmonary exacerbation
74. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis
75. Isolation of angiopoietin-1, a ligand for the Tie2 receptor, by secretion trap cloning
76. Requisite role of angiopoietin-1, a ligand for the Tie-2 receptor, during embryonic angiogenesis
77. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis
78. Angiopoietins 3 and 4: Diverging gene counterparts in mice and humans
79. Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, Tek, reveal a critical role in vasculogenesis of the embryo
80. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation
81. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1
82. Angiopoietin-1 is an anti-permeability and anti-inflammatory agent in vivo and targets cell junctions
83. Analysis of blood vessel maturation processes during cyclic ovarian angiogenesis
84. Cooperative roles for the angiopoietins and vascular endothelial growth factor in ovarian angiogenesis
85. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF
86. Angiopoietin 2 expression in the retina: Upregulation during physiologic and pathologic neovascularization
87. Changes in expression of vascular endothelial growth factor and angiopoietin-1 and -2 in the macaque corpus luteum during the menstrual cycle
88. Induction of angiopoietin and tie receptor mRNA expression after cerebral ischemia-reperfusion
89. VEGF and flt: Expression time kinetics in rat brain infarct
90. Rapid induction of vascular endothelial growth factor gene expression after transient middle cerebral artery occlusion in rats
91. Vascular endothelial growth factor expression in transient focal cerebral ischemia in the rat
92. Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) following permanent and transient occlusion of the middle cerebral artery in the rat
93. Vascular endothelial growth factor and its receptor, KDR, in human brain tissue after ischemic stroke
94. Expression of vascular endothelial growth factor mRNA following transient forebrain ischemia in rats
95. Vascular endothelial growth factor upregulation in transient global ischemia induced by cardiac arrest and resuscitation in rat brain
96. Cell type specific upregulation of vascular endothelial growth factor in an MCA-occlusion model of cerebral infarct
97. Angiopoietins and Tie receptors are upregulated after transient middle cerebral artery occlusion
98. Reduction of ischemic damage by application of vascular endothelial growth factor in rat brain after transient ischemia
99. Vascular endothelial cell growth factors promote the in vivo development of rat photoreceptor cells
100. Receptor tyrosine kinase tie 1 mRNA is upregulated on cerebral microvessels after embolic middle cerebral artery occlusion in rat
101. Evidence for modulation of genes involved in vascular adaptation by prolonged exposure of endothelial cells to shear stress
102. Regulation of angiopoietin-2 mRNA levels in bovine microvascular endothelial cells by cytokines and hypoxia
103. Hypoxia induced pivotal tumor angiogenesis control factors including p53, vascular endothelial growth factor and the NFκB-dependent inducible nitric oxide synthase and cyclo-oxygenase-2
104. Hypoxia and interleukin-1β stimulate vascular endothelial growth factor production in human proximal tubular cells
105. Expression of angiopoietin-2 by human endometrial cells: Regulation by hypoxia and inflammation
106. Hypoxia-inducible angiopoietin-2 expression is mimicked by iodonium compounds and occurs in the rat brain and skin in response to systemic hypoxia and tissue ischemia
107. Hypoxia and vascular endothelial growth factor selectively up-regulate angiopoietin-2 in bovine microvascular endothelial cells
108. Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1α→hypoxia response element→VEGF cascade differentially regulates vascular response and growth rate in tumors
109. Hypoxia upregulates angiopoietin-2, a tie-2 ligand, in mouse mesangial cells
110. Induction of hypoxia-inducible factor-1 (HIF-1) and its target genes following focal ischaemia in rat brain
111. Clinical applications of angiogenic growth factors and their inhibitors
112. VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain
113. Induction of vascular endothelial growth factor by hypoxia is modulated by a phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-ras-transformed cells through a hypoxia-inducible factor-1 transcriptional element
114. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation
115. VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain
116. Vascular endothelial growth factor is essential for corpus luteum angiogenesis